AU567236B2 - Pharmaceutical formulation of tissue plasminogen activator - Google Patents

Pharmaceutical formulation of tissue plasminogen activator

Info

Publication number
AU567236B2
AU567236B2 AU57964/86A AU5796486A AU567236B2 AU 567236 B2 AU567236 B2 AU 567236B2 AU 57964/86 A AU57964/86 A AU 57964/86A AU 5796486 A AU5796486 A AU 5796486A AU 567236 B2 AU567236 B2 AU 567236B2
Authority
AU
Australia
Prior art keywords
ser
gly
leu
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57964/86A
Other languages
English (en)
Other versions
AU5796486A (en
Inventor
Henry Berger
Michael Denis Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU5796486A publication Critical patent/AU5796486A/en
Application granted granted Critical
Publication of AU567236B2 publication Critical patent/AU567236B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU57964/86A 1985-05-28 1986-05-27 Pharmaceutical formulation of tissue plasminogen activator Ceased AU567236B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB8513358 1985-05-28
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation
GB8521705 1985-08-31

Publications (2)

Publication Number Publication Date
AU5796486A AU5796486A (en) 1986-12-04
AU567236B2 true AU567236B2 (en) 1987-11-12

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57964/86A Ceased AU567236B2 (en) 1985-05-28 1986-05-27 Pharmaceutical formulation of tissue plasminogen activator

Country Status (22)

Country Link
US (2) US4929444A (enExample)
JP (1) JPH0759517B2 (enExample)
AU (1) AU567236B2 (enExample)
BE (1) BE904830A (enExample)
CA (1) CA1300008C (enExample)
CH (1) CH665356A5 (enExample)
DE (1) DE3617752A1 (enExample)
DK (1) DK163173C (enExample)
ES (2) ES8800601A1 (enExample)
FI (1) FI85335C (enExample)
FR (1) FR2583984B1 (enExample)
GB (1) GB2176702B (enExample)
GR (1) GR861366B (enExample)
HU (1) HU195733B (enExample)
IL (1) IL78938A (enExample)
IT (1) IT1191926B (enExample)
LU (1) LU86444A1 (enExample)
NL (1) NL8601355A (enExample)
NO (1) NO171345C (enExample)
NZ (1) NZ216307A (enExample)
PT (1) PT82646B (enExample)
SE (1) SE462016B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
AU600724B2 (en) * 1986-05-12 1990-08-23 Boehringer Ingelheim International Gmbh Novel combination
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
ES2217340T3 (es) * 1995-12-13 2004-11-01 The Children's Medical Center Corporation Inhibidor de la proliferacion de celulas endoteliales y utilizacion de este.
DE69719265T2 (de) * 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
CN1553811A (zh) * 2001-09-07 2004-12-08 ӡ�����Ƽ��ɷ����޹�˾ 人组织尿激酶类型纤溶酶原激活物制剂
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
AU2004253882B2 (en) * 2003-06-20 2010-06-10 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
PT1879599E (pt) * 2005-04-20 2014-01-23 Hutchinson Fred Cancer Res Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5330286A (en) * 1985-02-09 1986-08-14 Beecham Group Plc Modified tissue-type plasminogen activator
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (enExample) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
GB2138824B (en) * 1982-10-29 1986-12-31 Mitsui Toatsu Chemicals Novel plasminogen activator process for its preparation and thrombolytic drug containing the same
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
AU5330286A (en) * 1985-02-09 1986-08-14 Beecham Group Plc Modified tissue-type plasminogen activator

Also Published As

Publication number Publication date
LU86444A1 (fr) 1986-12-05
GB2176702B (en) 1989-07-05
FR2583984A1 (fr) 1987-01-02
JPH0759517B2 (ja) 1995-06-28
SE8602405L (sv) 1986-11-29
DK163173B (da) 1992-02-03
JPH06183995A (ja) 1994-07-05
AU5796486A (en) 1986-12-04
SE8602405D0 (sv) 1986-05-27
NO171345C (no) 1993-03-03
GB8612780D0 (en) 1986-07-02
NO862096L (no) 1986-12-01
FI85335C (fi) 1992-04-10
PT82646B (pt) 1989-01-30
CH665356A5 (de) 1988-05-13
FI862227A0 (fi) 1986-05-27
IL78938A0 (en) 1986-09-30
US4968617A (en) 1990-11-06
NL8601355A (nl) 1986-12-16
BE904830A (fr) 1986-11-27
ES557374A0 (es) 1988-06-01
ES8800601A1 (es) 1987-11-16
ES8802439A1 (es) 1988-06-01
FR2583984B1 (fr) 1989-06-02
DK246786D0 (da) 1986-05-27
GB2176702A (en) 1987-01-07
NO171345B (no) 1992-11-23
GR861366B (en) 1986-09-29
FI862227L (fi) 1986-11-29
FI85335B (fi) 1991-12-31
ES555353A0 (es) 1987-11-16
DK246786A (da) 1986-11-29
US4929444A (en) 1990-05-29
DK163173C (da) 1992-06-22
PT82646A (en) 1986-06-01
HU195733B (en) 1988-07-28
IT1191926B (it) 1988-03-31
NZ216307A (en) 1989-10-27
IT8648065A0 (it) 1986-05-27
HUT41638A (en) 1987-05-28
DE3617752C2 (enExample) 1988-06-30
SE462016B (sv) 1990-04-30
DE3617752A1 (de) 1986-12-04
IL78938A (en) 1993-02-21
CA1300008C (en) 1992-05-05

Similar Documents

Publication Publication Date Title
AU5796486A (en) Pharmaceutical formulation of tissue plasminogen activator
AU588365B2 (en) Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
AU571372B2 (en) Gel based delivery of active substances
AU609390B2 (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
AU569429B2 (en) Aqueous acidic tissue plasminogen activator parenternal formulation
AU4434589A (en) Pharmaceutical compositions containing salts of cholesterol hemisuccinate
AU6110286A (en) Poly-kringle plasminogen activator
AU581010B2 (en) Novel pharmaceutical use of (NVA)``-cyclosporine
EP0196920A3 (en) Degraded species of tissue-type plasminogen activator, pharmaceutical composition and method of preparation
AU6806487A (en) Tissue plasminogen activator
AU2690684A (en) Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
ZA867839B (en) Biologically active derivatives of human ypsilon-interferon
AU6180486A (en) Novel tissue plasminogen activator derivatives
AU4486189A (en) Oral liquid pharmaceutical compositions of sulindac
AU570582B2 (en) Pharmaceutical composition of flupirtine and 4-acetamidophenol
AU5953090A (en) Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents
AU1892788A (en) Improvements relating to measurement of tissue plasminogen activator activity
ZA863956B (en) Pharmaceutical formulations containing tissue plasminogen activator
AU6656886A (en) Pharmaceutical composition of suprofen
AU608232C (en) Modified tissue plasminogen activator
AU7090787A (en) Tissue plasminogen activator
IL79521A0 (en) Pharmaceutical dosage unit of tissue plasminogen activator
AU563031C (en) Human Tissue Plasminogen Activator
AU563031B2 (en) Human tissue plasminogen activator
IL78450A0 (en) Agent containing tissue plasminogen activator(t-pa)